Longeveron Inc. (LGVN)
After hours:
| Previous Close | 3.9000 |
| Open | 3.6900 |
| Bid | 3.2200 x 2400 |
| Ask | 3.2700 x 2400 |
| Day's Range | 3.1100 - 3.7500 |
| 52 Week Range | 0.7707 - 36.5000 |
| Volume | |
| Avg. Volume | 10,114,397 |
| Market Cap | 31.203M |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.6000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.58 |
GlobeNewswireLongeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,236,026 shares of its Class A common stock (or common stock equivalents in lieu thereof) at a purchase price of $4.025 per share of Cla
GlobeNewswireLongeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
Wa'el Hashad Wa'el Hashad, CEO, Longeveron – FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ – – Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease after Regenerative Medicine Advanced Therapeutics (RMAT) Designation announced on July 9, 2024 – – Phase 2a Lomecel-B™ data in mild Alzheimer’s Disease selected for Featured Research Session oral presentation and poster presentation at upcoming Alzheimer’s Ass
- GlobeNewswire
Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
- Lomecel-B™ appears to be the first cellular therapeutic candidate to receive RMAT designation for Alzheimer’s Disease Wa'el Hashad Wa'el Hashad, CEO, Longeveron Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular ther
